Back to search results

Home Test for Alzheimer's Biomarker p-tau217

This study is developing a new home test for Alzheimer's disease using a device called Tasso Lancet. It aims to measure p-tau217, a biomarker (a biological sign) for Alzheimer's, from a small blood sample collected at home. Researchers will compare the p-tau217 levels from the Tasso device with levels from standard blood draws (venipuncture). You may be eligible if you are between 40 and 90 years old and have confirmed Alzheimer's disease (AD Amyloid PET/CSF confirmed), are a healthy control, or have amyloid-negative cognitive impairment. The main goal is to see if the Tasso device gives similar results to traditional blood tests. The study is currently unclear on its recruitment status and plans to enroll 1000 participants.

Study design
This is an observational study, meaning no intervention is given. It plans to enroll 1000 participants.
What's involved
You would provide blood samples using both the Tasso device and standard venipuncture at one visit.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07701161

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

Recruiting
Not specifiedAges 40–90Observational
Neurogen Biomarking LLC
~1,000 participants
Updated 2026-07-14 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Agreement between p-tau217 concentration in Tasso device capillary blood and venipuncture blood
Measured over Baseline

Conditions

Alzheimer s Disease
MCI Conversion to Dementia
pTau217
Biomarkers

Explore related trials

Alzheimer's DiseaseDementiaMild cognitive disorderAmyloidp-tau217

NCT07701161

Where you'd take part

This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Insigth Hospital and Medical Center Chicago

    Chicago, Illinoisstudy coordinator listed

    Recruiting

  • Insight Hospital and Medical Center Dearborn

    Dearborn, Michiganno site contact published

    Active, not recruiting

  • Insight Institute of Neurology and Neurosurgery

    Flint, Michiganno site contact published

    Active, not recruiting

  • Memorial Healthcare Hospital

    Owosso, Michiganno site contact published

    Active, not recruiting

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolinano site contact published

    Active, not recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Rany Aburashed · PRINCIPAL_INVESTIGATOR · Insight Health Systems

Who to contact

Ansam Eghzawi, MD
[email protected]
+18109410076
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed

Exclusion

Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use

What this trial measures

  • Agreement between p-tau217 concentration in Tasso device capillary blood and venipuncture bloodBaseline

    Mean, mean fold-change, and effect size of p-tau217 in Tasso samples between AD and non-AD groups.